Cargando…

CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!”

Kidneys are one of the most frequently transplanted human organs. Immunosuppressive agents may prevent or reverse most acute rejection episodes; however, the graft may still succumb to chronic rejection. The immunological response involved in the chronic rejection process depends on both innate and...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Marcos V., Machado, Juliana R., Rocha, Laura P., Castellano, Lúcio R., Reis, Marlene A., Corrêa, Rosana R. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376773/
https://www.ncbi.nlm.nih.gov/pubmed/22720132
http://dx.doi.org/10.1155/2012/203780
_version_ 1782235866241957888
author Silva, Marcos V.
Machado, Juliana R.
Rocha, Laura P.
Castellano, Lúcio R.
Reis, Marlene A.
Corrêa, Rosana R. M.
author_facet Silva, Marcos V.
Machado, Juliana R.
Rocha, Laura P.
Castellano, Lúcio R.
Reis, Marlene A.
Corrêa, Rosana R. M.
author_sort Silva, Marcos V.
collection PubMed
description Kidneys are one of the most frequently transplanted human organs. Immunosuppressive agents may prevent or reverse most acute rejection episodes; however, the graft may still succumb to chronic rejection. The immunological response involved in the chronic rejection process depends on both innate and adaptive immune response. T lymphocytes have a pivotal role in chronic rejection in adaptive immune response. Meanwhile, we aim to present a general overview on the state-of-the-art knowledge of the strategies used for manipulating the lymphocyte activation mechanisms involved in allografts, with emphasis on T-lymphocyte costimulatory and coinhibitory molecules of the B7-CD28 superfamily. A deeper understanding of the structure and function of these molecules improves both the knowledge of the immune system itself and their potential action as rejection inducers or tolerance promoters. In this context, the central role played by CD28 family, especially the relationship between CD28 and CTLA-4, becomes an interesting target for the development of immune-based therapies aiming to increase the survival rate of allografts and to decrease autoimmune phenomena. Good results obtained by the recent development of abatacept and belatacept with potential clinical use aroused better expectations concerning the outcome of transplanted patients.
format Online
Article
Text
id pubmed-3376773
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33767732012-06-20 CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!” Silva, Marcos V. Machado, Juliana R. Rocha, Laura P. Castellano, Lúcio R. Reis, Marlene A. Corrêa, Rosana R. M. J Transplant Review Article Kidneys are one of the most frequently transplanted human organs. Immunosuppressive agents may prevent or reverse most acute rejection episodes; however, the graft may still succumb to chronic rejection. The immunological response involved in the chronic rejection process depends on both innate and adaptive immune response. T lymphocytes have a pivotal role in chronic rejection in adaptive immune response. Meanwhile, we aim to present a general overview on the state-of-the-art knowledge of the strategies used for manipulating the lymphocyte activation mechanisms involved in allografts, with emphasis on T-lymphocyte costimulatory and coinhibitory molecules of the B7-CD28 superfamily. A deeper understanding of the structure and function of these molecules improves both the knowledge of the immune system itself and their potential action as rejection inducers or tolerance promoters. In this context, the central role played by CD28 family, especially the relationship between CD28 and CTLA-4, becomes an interesting target for the development of immune-based therapies aiming to increase the survival rate of allografts and to decrease autoimmune phenomena. Good results obtained by the recent development of abatacept and belatacept with potential clinical use aroused better expectations concerning the outcome of transplanted patients. Hindawi Publishing Corporation 2012 2012-06-07 /pmc/articles/PMC3376773/ /pubmed/22720132 http://dx.doi.org/10.1155/2012/203780 Text en Copyright © 2012 Marcos V. Silva et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Silva, Marcos V.
Machado, Juliana R.
Rocha, Laura P.
Castellano, Lúcio R.
Reis, Marlene A.
Corrêa, Rosana R. M.
CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!”
title CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!”
title_full CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!”
title_fullStr CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!”
title_full_unstemmed CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!”
title_short CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!”
title_sort cd28 family and chronic rejection: “to belatacept...and beyond!”
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376773/
https://www.ncbi.nlm.nih.gov/pubmed/22720132
http://dx.doi.org/10.1155/2012/203780
work_keys_str_mv AT silvamarcosv cd28familyandchronicrejectiontobelataceptandbeyond
AT machadojulianar cd28familyandchronicrejectiontobelataceptandbeyond
AT rochalaurap cd28familyandchronicrejectiontobelataceptandbeyond
AT castellanolucior cd28familyandchronicrejectiontobelataceptandbeyond
AT reismarlenea cd28familyandchronicrejectiontobelataceptandbeyond
AT correarosanarm cd28familyandchronicrejectiontobelataceptandbeyond